Compare Incyte Corporation (INCY) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs PulteGroup, Inc. — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while PulteGroup, Inc. trades at $123.59 (market cap $23.46B). The key difference: Incyte Corporation and PulteGroup, Inc. are close in size by market cap, and PulteGroup, Inc. pays a 0.84% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PHM | |
|---|---|---|
Market Cap | $23.11B | $23.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $142.56 |
52-Week Low | $67.38 | $108.65 |
Enterprise Value | $19.13B | $23.42B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
PulteGroup (PHM) trades at $123.12, down 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows solid fundamentals with a P/E of 12.19, net income margin of 12.14%, and positive cash flow trends, though recent earnings missed expectations in two of the last three quarters. Recent news highlights mixed investor sentiment amid mortgage rate concerns and new community developments, with a dividend payment scheduled for July 2, 2026.
Outlook is cautiously optimistic with a consensus price target of $146.50, implying 19% upside, supported by strong institutional holdings and a GF Score of 93. Key risks include high mortgage rates pressuring margins and volatile housing demand. The stock's current level near the analyst low target of $123.00 suggests potential support, but earnings performance in the upcoming Q2 report will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
